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Abstract
Background: Interpretation of serological assays in Lyme borreliosis requires an understanding of the clinical
indications and the limitations of the currently available tests. We therefore systematically reviewed the accuracy of
serological tests for the diagnosis of Lyme borreliosis in Europe.
Methods: We searched EMBASE en MEDLINE and contacted experts. Studies evaluating the diagnostic accuracy of
serological assays for Lyme borreliosis in Europe were eligible. Study selection and data-extraction were done by
two authors independently. We assessed study quality using the QUADAS-2 checklist. We used a hierarchical
summary ROC meta-regression method for the meta-analyses. Potential sources of heterogeneity were test-type,
commercial or in-house, Ig-type, antigen type and study quality. These were added as covariates to the model, to
assess their effect on test accuracy.
Results: Seventy-eight studies evaluating an Enzyme-Linked ImmunoSorbent assay (ELISA) or an immunoblot assay
against a reference standard of clinical criteria were included. None of the studies had low risk of bias for all
QUADAS-2 domains. Sensitivity was highly heterogeneous, with summary estimates: erythema migrans 50 % (95 %
CI 40 % to 61 %); neuroborreliosis 77 % (95 % CI 67 % to 85 %); acrodermatitis chronica atrophicans 97 % (95 % CI
94 % to 99 %); unspecified Lyme borreliosis 73 % (95 % CI 53 % to 87 %). Specificity was around 95 % in studies
with healthy controls, but around 80 % in cross-sectional studies. Two-tiered algorithms or antibody indices did not
outperform single test approaches.
Conclusions: The observed heterogeneity and risk of bias complicate the extrapolation of our results to clinical
practice. The usefulness of the serological tests for Lyme disease depends on the pre-test probability and
subsequent predictive values in the setting where the tests are being used. Future diagnostic accuracy studies
should be prospectively planned cross-sectional studies, done in settings where the test will be used in practice.
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Background
Lyme borreliosis is one of the most prevalent vector-
borne diseases in Europe. Its incidence varies between
countries, with approximately 65,500 patients annually
in Europe (estimated in 2009) [1]. It is caused by spiro-
chetes of the Borrelia burgdorferi sensu lato species
complex, which are transmitted by several species of
Ixodid ticks [2]. In Europe, at least five genospecies of
the Borrelia burgdorferi sensu lato complex can cause
disease, leading to a variety of clinical manifestations
including erythema migrans (EM), neuroborreliosis, arthritis
and acrodermatitis chronica atrophicans (ACA). Each of
these clinical presentations can be seen as a distinct target
condition, i.e. the disorder that a test tries to determine, as
they affect different body parts and different organ systems,
and because the patients suffering from these conditions
may enter and travel through the health care system in
different ways, hence following different clinical pathways.
The diagnosis of Lyme borreliosis is based on the pres-
ence of specific symptoms, combined with laboratory evi-
dence for infection. Laboratory confirmation is essential
in case of non-specific disease manifestations. Serology is
the cornerstone of Lyme laboratory diagnosis, both in pri-
mary care and in more specialized settings. Serological
tests that are most often used are enzyme-linked immuno-
sorbent assays (ELISAs) or immunoblots. ELISAs are the
first test to be used; immunoblots are typically applied
only when ELISA was positive. If signs and symptoms are
inconclusive, the decision may be driven by the serology
test results. In such a situation, patients may be treated
with antibiotics after a positive serology result – a positive
ELISA possibly followed by a positive immunoblot. After
negative serology – a negative ELISA or a positive ELISA
followed by a negative immunoblot – patients will not be
treated for Lyme borreliosis, but they will be followed up
or referred for further diagnosis. This implies that false
positively tested patients (who have no Lyme borreliosis,
but have positive serology) will be treated for Lyme borre-
liosis while they have another condition. It also implies
that falsely negative tested patients (who have the disease,
but test negative) will not be treated for Lyme borreliosis.
A test with a high specificity – which is the percentage
true negative results among patients without the target
condition – will result in a low percentage of false posi-
tives. A test with a high sensitivity – being the percentage
true positives among patients with the target condition –
will result in a low percentage of false negatives.
The interpretation of serology results is complicated.
The link between antibody status and actual infection
may not be obvious: non-infected people may have immun-
ity and test positive, while infected people may have a delay
in their antibody response and may test negative. Further-
more, there is an overwhelming number of different avail-
able assays that have all been evaluated in different patient
populations and settings and that may perform differently
for the various disease manifestations [3]. We therefore
systematically reviewed all available literature to assess the
accuracy (expressed as sensitivity and specificity) of sero-
logical tests for the diagnosis of the different manifestations
of Lyme borreliosis in Europe. Our secondary aim was to
investigate potential sources of heterogeneity, for example
test-type, whether the test was a commercial test or an in-
house test, publication year and antigens used.
Methods
We searched EMBASE and Medline (Appendix 1) and
contacted experts for studies evaluating serological tests
against a reference standard. The reference standard is
the test or testing algorithm used to define whether
someone has Lyme borreliosis or not. We included studies
using any reference standard, but most studies used clinical
criteria, sometimes in combination with serology. Studies
performed in Europe and published in English, French,
German, Norwegian, Spanish and Dutch were included.
The ideal study type to answer our question would be
a cross-sectional study, including a series of representa-
tive, equally suspected patients who undergo both the
index test and the reference standard [4]. Such studies
would provide valid estimates of sensitivity and specifi-
city and would also directly provide estimates of preva-
lence and predictive values. However, as we anticipated
that these cross-sectional studies would be very sparse,
we decided to include case-control studies or so-called
two-gate designs as well [5]. These studies estimate the
sensitivity of a test in a group of cases, i.e. patients for
whom one is relatively sure that they have Lyme borre-
liosis. They estimate the specificity in a group of con-
trols, i.e. patients of whom one is relatively sure that
they do not have Lyme borreliosis. These are healthy
volunteers, or patients with other diseases than Lyme.
We included studies on ELISAs, immunoblots, two-tiered
testing algorithms of an ELISA followed by an immunoblot,
and specific antibody index measurement (calculated using
the antibody titers in both serum and cerebrospinal fluid).
We excluded indirect fluorescent antibody assays, as these
are rarely used in practice. Studies based on make-up
samples were excluded. We also excluded studies for which
2 × 2 tables could not be inferred from the study results.
For each article, two authors independently collected
study data and assessed quality. We assessed the quality
using the Quality Assessment of Diagnostic Accuracy
Studies-2 (QUADAS-2) checklist. This checklist consists
of four domains: patient selection, index test, reference
standard and flow and timing [6]. Each of these domains
has a sub-domain for risk of bias and the first three have
a sub-domain for concerns regarding the applicability of
study results. The sub-domains about risk of bias include
a number of signalling questions to guide the overall
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judgement about whether a study is highly likely to be
biased or not (Appendix 2).
We analysed test accuracy for each of the manifesta-
tions of Lyme borreliosis separately and separately for
case-control designs and cross-sectional designs. If a
study did not distinguish between the different manifes-
tations, we used the data of this study in the analysis for
the target condition “unspecified Lyme”. Serology assays
measure the level of immunoglubulins (Ig) in the patient’s
serum. IgM is the antibody most present in the early
stages of disease, while IgG increases later in the disease.
Some tests only measure IgM, some only IgG and some
tests measure any type of Ig. In some studies, the accuracy
was reported for IgM only, IgG only and for detection of
IgG and IgM. In those cases, we included the data for sim-
ultaneous detection of both IgG and IgM (IgT).
We meta-analyzed the data using the Hierarchical
Summary ROC (HSROC) model, a hierarchical meta-
regression method incorporating both sensitivity and
specificity while taking into account the correlation be-
tween the two [7]. The model assumes an underlying
summary ROC curve through the study results and esti-
mates the parameters for this curve: accuracy, threshold
at which the tests are assumed to operate and shape of
the curve. Accuracy is a combination of sensitivity and
specificity; the shape of the curve provides information
about how accuracy varies when the threshold varies.
From these parameters we derived the reported sensitiv-
ity and specificity estimates. We used SAS 9.3 for the
analyses and Review Manager 5.3 for the ROC plots.
There is no recommended measure to estimate the
amount of heterogeneity in diagnostic accuracy reviews,
but researchers are encouraged to investigate potential
sources of heterogeneity [7]. The most prominent source
of heterogeneity is variation in threshold, which is taken
into account by using the HSROC model. Other potential
sources of heterogeneity are: test type (ELISA or immuno-
blot); a test being commercial or not; immunoglobulin
type; antigen used; publication year; late versus early dis-
ease; and study quality. These were added as covariates to
the model to explain variation in accuracy, threshold or
shape of the curve.
Some studies reported results for patients with “pos-
sible Lyme” (i.e. no clear cases, neither clear controls).
We included these as cases. As this may lead to under-
estimation of sensitivity, we investigated the effect of this
approach. Borderline test results were included in the
test-positive group.
Results
Selection and quality assessment
Our initial search in January 2013 retrieved 8026 unique
titles and a search update in February 2014 revealed an-
other 418 titles. After careful selection by two authors
independently (ML, HS) we read the full text of 489
studies, performed data-extraction on 122 studies and
finally included 75 unique published articles (Fig. 1).
Fifty-seven of these had a case-control design, compar-
ing a group of well-defined cases with a group of healthy
controls or controls with diseases that could lead to
cross-reactivity of the tests [8–64]. Eighteen had a cross-
sectional design in which a more homogeneous sample
of patients underwent both the serological assay(s) and
the reference standard [65–82]. Three studies were not
used in the meta-analyses, either because they used im-
munoblot as a reference standard [76, 79], or included
asymptomatic cross-country runners with high IgG titers
as controls [47].
None of the studies had low risk of bias in all four
QUADAS-2 domains (Fig. 2 and Tables 1 and 2). Forty-
six out of the 57 case-control studies and six out of the
18 cross-sectional studies scored unclear or high risk of
bias in all four domains. All case-control studies had a
high risk of bias for the patient sampling domain,
because these designs exclude all “difficult to diagnose”
patients [83]. Only three studies reported that the as-
sessment of the index test was blinded for the disease
status of the participants [45, 66, 75]. The cut-off value
to decide whether a test is positive or negative was often
decided after the study was done, which may also lead to
bias in the index test domain [84]. The most common
problem was inclusion of the serology results in the refer-
ence standard. The flow and timing domain was problem-
atic in all case-control studies, as the cases and controls
are usually verified in different ways. Three studies re-
ported potential conflict of interest [31, 39, 62]. Most
studies had a high concern regarding applicability, which
means that either the included patients or the test used
are not representative for clinical practice. Only three
studies were representative for all domains [65, 73, 81].
Meta-analyses
Erythema migrans
Nineteen case-control studies including healthy controls
evaluated the accuracy of serological tests for EM. The
summary sensitivity for ELISA or immunoblot detecting
EM patients was 50 % (95 % CI 40 % to 61 %) and specifi-
city 95 % (95 % CI 92 % to 97 %). ELISA tests had a higher
accuracy than immunoblots (P-value = 0 · 008), mainly due
to a higher sensitivity (Table 3). Commercial tests did not
perform significantly different from in-house tests. The 23
case-control studies on EM including cross-reacting con-
trols had similar results (data not shown). One cross-
sectional study done on EM-suspected patients evaluated
four different immunoblots in patients with a positive or
unclear ELISA result; their sensitivity varied between 33
and 92 % and their specificity between 27 and 70 % [66].
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Neuroborreliosis
Twenty case-control studies on neuroborreliosis in-
cluded healthy controls. Their overall sensitivity was
77 % (95 % CI 67 % to 85 %) and their specificity 93 %
(95 % CI 88 % to 96 %) (Fig. 3a). On average, ELISA assays
had a lower accuracy than immunoblot assays (P = 0 · 042).
The in-house ELISAs had the lowest specificity of all tests
(Table 3). Twenty-six case-control studies with cross-
reacting controls showed similar results, but with a lower
specificity (data not shown). The ten cross-sectional studies
Embase + Medline 
n=6441 
Database Ram 
Dessau n=6804
Database Nathalie van 
Burgel n=2715
8026 unique titles 
Screening of titles 
and abstracts  
n=4005+418=4423
Removal of irrelevant titles 
n=4021 
(veterinary papers, other 
diseases, etc) 
Thesis containing an 
evaluation study 
Removal of irrelevant titles 
n=3924 
(veterinary papers, other 
diseases, non-Lyme 
borrelia, etc)
Full texts retrieved 
n=489
Full text not retrieved  
n=11
Eligible for data-
extraction 
n=122 
Removal of irrelevant titles 
n=367 
(not accuracy, not clinical, 
not European, non-eligible 
languages, no ELISA or 
immonoblot) 
Search update in Feb 
2014 n=418 
Included in review: 
n=75
47 studies excluded: 
technical evaluations; 2x2 
tables not available. 
Fig. 1 Results of the search and selection process
Fig. 2 Methodological quality graph. Review authors’ judgements about each methodological quality item presented as percentages across all
included studies. On the left-hand side the judgements for the included case control studies; and on the right-hand side those for the included
cross-sectional studies. RoB: Risk of Bias; CrA: Concerns regarding applicability; P: patient sampling; I: Index test; RS: Reference Standard; TaF: timing and flow
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Table 1 Quality assessment of included case control studies
Author Year Design RoB_P CrA_P RoB_I CrA_I RoB_RS CrA_RS RoB_TaF
Ang 2011 Case control High High Unclear Low Unclear Low High
Ang 2012 Case control High High Unclear Low Unclear Low High
Bergstrom 1991 Case control High High High High High Low High
Branda 2013 Case control High High Unclear Low High Low High
Cerar 2006 Case control High High Unclear Low Low Low High
Cerar 2010 Case control High High Unclear Low Unclear Low High
Christova 2003 Case control High High Unclear Low Unclear Low High
Cinco 2006 Case control High High Unclear Low Unclear Low High
Dessau 2010 Case control High High Unclear Low High Low High
Dessau 2013 Case control High High Unclear Low High Low High
Flisiak 1996 Case control High High Unclear Low Low Low High
Flisiak 1998 Case control High High Unclear Low Low Low High
Goettner 2005 Case control High High Unclear High High Low High
Goossens 2000 Case control High High Unclear Low Unclear Low High
Goossens 2001 Case control High High Unclear Low Unclear Low High
Gueglio 1996 Case control High High Unclear Low Unclear Low High
Hansen 1988 Case control High High High High Unclear Low High
Hansen 1989 Case control High High High High Low Low High
Hansen 1991 Case control High High High Low Low Low High
Hernandez 2003 Case control High High Unclear Low Unclear Low High
Hofmann 1990 Case control High High Unclear Low Unclear Low High
Hofmann 1996 Case control High High Unclear Low Unclear Low High
Hofstad 1987 Case control High High High High Low Low High
Hunfeld 2002 Case control High High Unclear Low Unclear Low High
Jovivic 2003 Case control High High High/Unclear* High Unclear Low High
Kaiser 1998 Case control High High High High High Low High
Kaiser 1999inf Case control High High High High High Low High
Karlsson 1989eur Case control High High High/Unclear* High Low Low High
Karlsson 1989siid Case control High High High High Low Low High
Lahdenne 2003 Case control High High High Low Unclear Low High
Lakos 2005 Case control High High Low High/Low* High Low High
Lange 1991 Case control High High Unclear High/Low* Unclear Low High
Lencakova 2008 Case control High High Low/Unclear* High/Low* Unclear Low High
Marangoni 2005jmm Case control High High Unclear Low Low Low High
Marangoni 2005new Case control High High Unclear Low* Low Low High
Marangoni 2008 Case control High High Unclear Unclear** Unclear Low High
Mathiesen 1996 Case control High High High/Low* High/Low* High Low High
Mathiesen 1998 Case control High High High/Unclear* High/Low* Low Low High
Nicolini 1992 Case control High High High High Unclear Low High
Nohlmans 1994 Case control High High High/Unclear* High/Low* Unclear Low High
Oksi 1995 Case control High High High/Unclear* High/Low* Unclear Low High
Olsson 1991 Case control High High High High Unclear Low High
Panelius 2001 Case control High High High High High Low High
Putzker 1995 Case control High High Unclear Low High Low High
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for neuroborreliosis had a median prevalence of 50 % (IQR
37 % to 70 %). The summary sensitivity for any serological
test done in serum was 78 % (95 % CI 53 % to 92 %) and
specificity was 78 % (95 % CI 40 % to 95 %) (Fig. 3b).
Whether a test was ELISA or immunoblot, commercial or
in-house did not affect model parameters.
Lyme Arthritis
Meta-analysis was not possible for the eight case-control
studies on Lyme arthritis with healthy controls. We
therefore only report the median estimates and their
interquartile range (IQR). Median sensitivity was 96 %
(IQR 93 % to 100 %); median specificity was 94 % (IQR
Table 1 Quality assessment of included case control studies (Continued)
Rauer 1995 Case control High High High High High Low High
Reiber 2013 Case control High High High Unclear Low Low High
Rijpkema 1994 Case control High High Unclear High/Low* Unclear Low High
Ruzic 2002 Case control High High Unclear Low Unclear Low High
Ryffel 1998 Case control High High Unclear High High Low High
Schulte 2004 Case control High High Unclear High High Low High
Smismans 2006 Case control High High Unclear Low High Low High
Tjernberg 2007 Case control High High Unclear Low/Unclear* High Low High
Tjernberg 2011 Case control High High Unclear Low High Low High
VanBurgel 2011 Case control High High Unclear Low High Low High
Wilske 1993 Case control High High High/Unclear* High/Low* High Low High
Wilske 1999 Case control High High Unclear High High Low High
Zoller 1990 Case control High High Unclear High Unclear Low High
RoB_P: Risk of Bias in patient sampling; RoB_I: Risk of Bias in Index test; RoB_RS: Risk of Bias in Reference Standard; RoB_TaF: Risk of Bias in timing and flow.
CrA_P: Concerns regarding applicability of patient sample; CrA_I: Concerns regarding applicability of Index Test; CrA_RS: Concerns regarding applicability of
Reference Standard. * some studies evaluated more than one test and evaluated these in different ways (e.g. for one test the cut-off value was pre-specified, while
for the other test it was based on the results)
Table 2 Quality assessment of included cross-sectional control studies
Author_Year Design RoB_P CrA_P RoB_I CrA_I RoB_RS CrA_RS RoB_TaF
Albisetti 1997 Cross sectional Low Low Unclear Low Low Low Unclear
Barrial 2011 Cross sectional Unclear Unclear Low Low Low Low Low
Bazovska 2001 Cross sectional Unclear Unclear Unclear Low Unclear Low Low
Bednarova 2006 Cross sectional Unclear Unclear Unclear Low Unclear Low Unclear
Bennet 2008 Cross sectional Unclear High Unclear Low Unclear Low Unclear
Blaauw 1993 Cross sectional Low Low High High Low Low Low
Blaauw 1999 Cross sectional Low High Unclear High/Low* Low Low Unclear
Blanc 2007 Cross sectional Unclear Unclear Unclear Low High Low Unclear
Cermakova 2005 Cross sectional Low Low Unclear Low High Low Low
Davidson 1999 Cross sectional Unclear Unclear Unclear High/Low* High High Low
Ekerfelt 2004 Cross sectional Unclear Unclear Low Low Unclear Low Unclear
Jansson 2005 Cross sectional Unclear Unclear Unclear Low High High Low
Kolmel 1992 Cross sectional Unclear Unclear Unclear Low High Low Unclear
Ljostad 2005 Cross sectional High High Unclear Unclear Low Low Low
Popperl 2000 Cross sectional Unclear Unclear Unclear Low High High Low
Roux 2007 Cross sectional High Unclear Unclear High/Low* Low High Unclear
Skarpaas 2007 Cross sectional Low Low High/Unclear* Low Unclear Low Unclear
Skogman 2008 Cross sectional Unclear Unclear High High Low Low Low
RoB_P: Risk of Bias in patient sampling; RoB_I: Risk of Bias in Index test; RoB_RS: Risk of Bias in Reference Standard; RoB_TaF: Risk of Bias in timing and flow.
CrA_P: Concerns regarding applicability of patient sample; CrA_I: Concerns regarding applicability of Index Test; CrA_RS: Concerns regarding applicability of
Reference Standard. * some studies evaluated more than one test and evaluated these in different ways (e.g. for one test the cut-off value was pre-specified, while
for the other test it was based on the results)
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Table 3 Summary estimates of sensitivity and specificity for all case-definitions, derived from a hierarchical summary ROC model. The results may be different from those in the
main text, as here they are specified for immunoblots and ELISAs and for commercial and in-house tests separately, while in the main text the overall estimates are provided
Case definition Assay Design N (studies); N(2×2
tables); N(cases);
N(controls)
Sensitivity (95 % CI) Specificity (95 % CI) Heterogeneity Quality and Study Design
Erythema
migrans
In-house ELISA Case-control,
Healthy controls
6, 10, 451, 658 0•41 (0•25 to 0•60) 0•97 (0•95 to 0•98) IgG lower sensitivity than IgM.
Other sources of heterogeneity
were not found.
Study quality did not
influence the accuracy
In-house IB 3, 3, 182, 380 0•52 (0•38 to 0•65) 0•98 (0•94 to 0•99)
Commercial
ELISA
13, 32, 874, 2509 0•54 (0•44 to 0•65) 0•93 (0•90 to 0•95)
Commercial IB 3, 5, 161, 289 0•58 (0•49 to 0•67) 0•86 (0•75 to 0•93)
Two-tiered tests 2, 7, 125, 190 range 0•12 to 0•64 range 0•67 to 0•96
Lyme
neuroborreliosis
In-house ELISA Case-control,
Healthy controls
6, 9, 277, 649 0•69 (0•60 to 0•76) 0•88 (0•72 to 0•97) IgM and IgG have similar sensitivity
and specificity, IgG has a higher
accuracy. Recombinant tests
perform best. More recent studies
perform better than earlier studies.
If serology was not part
of the reference standard,
then specificity was lower.
(serum) In-house IB 5, 8, 253, 445 0•69 (0•57 to 0•80) 0•93 (0•86 to 0•97)
Commercial
ELISA
11, 28, 484, 2920 0•81 (0•70 to 0•89) 0•94 (0•91 to 0•96)
Commercial IB 2, 4, 33, 286 0•81 (0•57 to 0•94) 0•92 (0•88 to 0•95)
Two-tiered tests 1, 5, 15, 100 range 0•41 to 0•87 range 0•88 to 0•94
(csf) Any ELISA Case-control,
Cross-reacting
controls
6, 9, 385, 261 0•74 (0•38 to 0•93) 0•96 (0•85 to 0•99)
(serum + csf) Specific AI test 7, 10, 458, 380 0•86 (0•63 to 0•95) 0•94 (0•85 to 0•97)
Lyme
neuroborreliosis
Any ELISA or IB
(in serum)
Cross-sectional
study
6, 12, 282, 412 0•78 (0•53 to 0•92) 0•78 (0•40 to 0•95) Sensitivity similar for IgG and IgM;
specifcity higher for IgG. No other
sources of heterogeneity.
Specific AI test
(in serum and
CSF)
4, 4, 102, 118 0•79 (0•34 to 0•97) 0•96 (0•64 to 1•00)
Lyme arthritis All ELISA Case-control,
Healthy controls
8, 26, 160, 1112 Median0•96Interquartile
range 0•93 to 1•00
Median
0•94Interquartile
range 0•91 to 0•97
IgM a much lower sensitivity than IgG.
No other sources of heterogeneity.
Study quality did not
influence the accuracy
Acrodermatitis All ELISA Case-control,
Healthy controls
10, 27, 256, 1415 0•97 (0•94 to 0•99) 0•95 (0•88 to 0•98) IgM a much lower sensitivity than IgG.
No other sources of heterogeneity.
Study quality did not
influence the accuracy
Lyme
borreliosis
(unspecified)
In-house ELISA Case-control,
Healthy controls
4, 7, 115, 215 0•85 (0•71 to 0•93) 0•98 (0•93 to 0•99) Tests assessing both IgM and IgG have
highest sensitivity; specificity not very
variable. Recombinant tests and more
recent studies perform worse.
If serology was not part
of the reference standard,
then accuracy was lower.In-house IB 2, 4, 98, 126 0•63 (0•33 to 0•86) 0•97 (0•93 to 0•99)
Commercial
ELISA
10, 43, 658, 815 0•70 (0•52 to 0•83) 0•95 (0•89 to 0•98)
Commercial IB 1, 4, 26, 62 0•29 (0•07 to 0•68) 0•96 (0•90 to 0•98)
Lyme
borreliosis
(unspecified)
Any ELISA or IB Cross-sectional
study
5, 14, 226, 914 0•77 (0•48 to 0•93) 0•77 (0•46 to 0•93) IgM lowest sensitivity, but highest
specificity; no other sources investigated.
Number of studies is for each combination of case definition and assay category. Thus the same study may appear more than once. ELISA Enzyme Immuno Assay, IB Immunoblot, AI Antibody Index, CSF
Cerebrospinal Fluid
Leeflang
et
al.BM
C
Infectious
D
iseases
 (2016) 16:140 
Page
7
of
17
91 % to 97 %) (Table 3). Three cross-sectional studies
were done in patients suspected of Lyme arthritis; this
was insufficient to do a meta-analysis [66, 71, 85].
Acrodermatitis chronica atrophicans
The nine case control studies on ACA including a
healthy control group had a high summary sensitivity for
any serological assay: 98 % (95 % CI 84 % to 100 %).
Specificity was 94 % (95 % CI 90 % to 97 %). One study
had an extremely low sensitivity for the in-house assay
evaluated; most likely because one of the antigens used
(OspC) is no longer expressed by the spirochetes in long-
standing disease [45]. Test-type was not added to the ana-
lyses, because of insufficient data. Case-control studies for
ACA including cross-reacting controls had a lower sensitivity
and specificity than the healthy control designs (both 91 %).
Unspecified Lyme borreliosis
Thirteen case-control studies included unspecified Lyme
borreliosis cases and healthy controls. Their summary
Fig. 3 Raw ROC plots and fitted summary ROC curves. Every symbol reflects a 2 × 2 table, one for each test. Blue triangle = commercial EIA; Red
diamond = in house EIA; Green rectangle = commercial IB; Black circle = in house IB. One study may have contributed more than one 2 × 2 table.
The dots on the summary ROC curves reflect the summary estimate of sensitivity and specificity. a neuroborreliosis case-control studies including
healthy controls. b: neuroborreliosis cross-sectional studies. c unspecified Lyme borreliosis case-control studies including healthy controls.
d unspecified Lyme borreliosis cross-sectional studies. The size of the symbol reflects the sample size. For the cross-sectional studies, only
the overall summary ROC curve is shown, while for the case-control designs the curves are shown for the different test-types
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sensitivity for any test was 73 % (95 % CI 53 % to 87)
and specificity was 96 % (95 % CI 91 % to 99 %) (Fig. 3c).
Commercial tests had a lower accuracy (P-value = 0 · 008),
mainly due to a lower sensitivity (Table 3). Twelve studies
including cross-reacting controls had a summary sensitivity
of 81 % (95 % CI 64 % to 91 %) and specificity of 90 %
(95 % CI 79 % to 96 %). Five cross-sectional studies aimed
to diagnose an unspecified form of Lyme borreliosis (Fig. 3d).
The prevalence varied between 10 and 79 %, indicating a
varying patient spectrum. Sensitivity was 77 % (95 % CI
48 % to 93 %) and specificity 77 % (95 % CI 46 % to 93 %).
There were insufficient data points to analyze test type.
Two-tiered tests
One case-control study investigated the diagnostic accur-
acy of two-tiered approaches for all manifestations and
healthy controls [11]. The sensitivity of the European algo-
rithms varied between 55 % for EM and 100 % for ACA.
The specificity for all assays was ≥ 99 %. Another case-
control study investigated 12 different algorithms for ‘late
Lyme borreliosis’ and ‘early Lyme borreliosis’ [21]. Their
sensitivity varied between 4 and 50 % and the specificity
varied between 88 and 100 %. One case-control study in-
cluding EM cases and healthy controls and evaluating two
algorithms reported a sensitivity of 11 % or 43 % and a
specificity of 100 % [14]. Two cross-sectional studies on
two-tiered tests aimed at diagnosing neuroborreliosis
[80, 81] and two at diagnosing unspecified Lyme borrelio-
sis [67, 70]. Their prevalence varied between 19 and 77 %;
their sensitivity between 46 and 97 %; and their specificity
between 56 and 100 %.
Specific antibody index
Seven studies containing cross-reacting controls evaluated
a specific antibody index for the diagnosis of neuroborre-
liosis. The summary sensitivity was 86 % (95 % CI 63 % to
95 %) and specificity 94 % (95 % CI 85 % to 97 %). The
four cross-sectional studies had a summary sensitivity of
79 % (95 % CI 34 % to 97 %) and a summary specificity of
96 % (95 % CI 64 % to 100 %).
Heterogeneity
The IgG tests had a comparable sensitivity to the IgM
tests, except for EM (IgM slightly higher sensitivity),
Lyme arthritis and ACA (IgM much lower sensitivity in
both). Tests assessing both IgM and IgG had the highest
sensitivity and the lowest specificity, although specificity
was above 80 % in most cases. (Table 4).
We evaluated the effect of three antigen types: whole
cell, purified proteins or recombinant antigens. In neu-
roborreliosis, recombinant antigens had both the highest
sensitivity and specificity, while in unspecified Lyme,
they had the lowest sensitivity and specificity. (Table 5)
Year of publication showed an effect only for erythema
migrans and neuroborreliosis: in both cases publications
before the year 2000 showed a lower sensitivity than
those after 2000. (Table 6) Antigen type and year of pub-
lication were not associated with each other.
For unspecified Lyme we were able to directly compare
the accuracy in early stages of disease with the accuracy in
later stages of disease. The tests showed a lower sensitivity
and slightly higher specificity in the early stages of
the disease. (Table 7).
We were able to meta-analyze manufacturer-specific re-
sults for only two manufacturers, but the results showed
much variability and the confidence intervals were broad.
We investigated the effect of the reference standard
domain of QUADAS-2: acceptable case definition versus
no or unclear; and serology in the case definition versus
no or unclear. None had a significant effect on accuracy.
The study by Ang contained at least 8 different 2x2
tables for each case definition and may have therefore
Table 4 Summary estimates of sensitivity and specificity for IgM versus IgG versus IGM or IgG (IgT)
IgM IgG IgT
Estimate (95 % CI) Estimate (95 % CI) Estimate (95 % CI)
Erythema migrans Sensitivity 0.426 (0.361 to 0.494) 0.359 (0.293 to 0.431) 0.606 (0.503 to 0.700)
Specifcitiy 0.953 (0.924 to 0.971) 0.961 (0.939 to 0.975) 0.919 (0.885 to 0.944)
Neuroborreliosis Sensitivity 0.600 (0.526 to 0.669) 0.589 (0.515 to 0.659) 0.865 (0.812 to 0.906)
Specifcitiy 0.949 (0.924 to 0.966) 0.956 (0.935 to 0.971) 0.913 (0.869 to 0.942)
Lyme arthritis Sensitivity 0.392 (0.279 to 0.517) 0.941 (0.857 to 0.977) 0.945 (0.842 to 0.982)
Specifcitiy 0.951 (0.881 to 0.980) 0.969 (0.942 to 0.983) 0.921 (0.837 to 0.964)
Acrodermatitis Chronica Atrophicans Sensitivity 0.184 (0.090 to 0.340) 0.987 (0.821 to 0.999) 0.978 (0.874 to 0.996)
Specifcitiy 0.965 (0.930 to 0.983) 0.966 (0.952 to 0.976) 0.932 (0.883 to 0.962)
Unspecified Lyme borreliosis* Sensitivity 0.596 (0.324 to 0.820) 0.557 (0.448 to 0.661) 0.792 (0.960 to 0.867)
Specifcitiy 0.911 (0.818 to 0.959) 0.986 (0.877 to 0.998) 0.947 (0.725 to 0.992)
IgT refers to assays measuring IgM and IgG simultaneously. 95 % CI = 95 % confidence interval. *Analyses were not possible for healthy controls; these are the
estimates for studies including cross-reacting controls
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weighed heavily on the results [8]. However, sensitivity
analysis showed that its effect was only marginal. The
same was true for assuming possible cases as being con-
trols and indeterminate test results as being negatives.
Discussion
Overall, the diagnostic accuracy of ELISAs and immuno-
blots for Lyme borreliosis in Europe varies widely, with an
average sensitivity of ~80 % and a specificity of ~95 %. For
Lyme arthritis and ACA the sensitivity was around 95 %.
For EM the sensitivity was ~50 %. In cross-sectional stud-
ies of neuroborreliosis and unspecified Lyme borreliosis,
the sensitivity was comparable to the case-control designs,
but the specificity decreased to 78 and 77 % respectively.
Two-tiered tests did not outperform single tests. Specific
antibody index tests did not outperform the other tests for
neuroborreliosis, although the specificity remained high
even in the cross-sectional designs. All results should be
interpreted with caution, as the results showed much vari-
ation and the included studies were at high risk of bias.
Although predictive values could not be meta-analyzed,
the sensitivity and specificity estimates from this review
may be used to provide an idea of the consequences of test-
ing when the test is being used in practice. Imagine that a
clinician sees about 1000 people a year who are suspected
of one of the manifestations of Lyme borreliosis, in a setting
where the expected prevalence of that manifestation is
10 %. A prevalence of 10 % would mean that 100 out of
1000 tested patients will really have a form of Lyme borre-
liosis. If these people are tested by an ELISA with a sensitiv-
ity 80 %, then 0.80*100 = 80 patients with Lyme borreliosis
will test positive and 20 patients will test negative. If we as-
sume a specificity of 80 % as well (following the estimates
from the cross-sectional designs), then out of the 900 pa-
tients without Lyme borreliosis, 0.80*900 = 720 will test
negative and 180 will test positive. These numbers mean
that in this hypothetical cohort of 1000 tested patients, 80
+ 180 = 260 patients will have a positive test result. Only 80
of these will be true positives and indeed have Lyme borre-
liosis (positive predictive value 80/260 = 0.31 = 31 %). The
other 180 positively tested patients are the false positives
and they will be treated for Lyme while they have another
cause of disease, thus delaying their final diagnosis and sub-
sequent treatment. In a two-tiered approach, all positives
will be tested with immunoblot after ELISA. These num-
bers also mean that we will have 720 + 20 = 740 negative
test results, of which 3 % (negative predictive value 720/
740 = 0.97 = 97 %) will have Lyme borreliosis despite a
negative test result. These are the false-negatives, their diag-
nosis will be missed or delayed. Although calculations like
these may provide insight in the consequences of testing,
they should be taken with caution. The results were overall
very heterogeneous and may depend on patient characteris-
tics. Also, the prevalence of 10 % may not be realistic. In
Table 5 Generation of antigens
Antigen Sensitivity (95 % CI) Specificity (95 % CI)
Erythema migrans Whole cell 0.515 (0.328 to 0.699) 0.957 (0.899 to 0.983)
Purified 0.579 (0.466 to 0.685) 0.950 (0.895 to 0.977)
Recombinant 0.551 (0.330 to 0.753) 0.947 (0.881 to 0.977)
Neuroborreliosis Whole cell 0.723 (0.555 to 0.845) 0.904 (0.792 to 0.959)
Purified 0.756 (0.614 to 0.858) 0.963 (0.935 to 0.979)
Recombinant 0.837 (0.647 to 0.935) 0.931 (0.881 to 0.960)
Lyme arthritis* Whole cell or Purified 0.952 (0.892 to 0.979) 0.958 (0.879 to 0.986)
Recombinant 0.954 (0.862 to 0.985) 0.927 (0.886 to 0.954)
Unspecified Lyme borreliosis Whole cell 0.703 (0.563 to 0.813) 0.950 (0.863 to 0.983)
Purified 0.836 (0.463 to 0.968) 0.965 (0.855 to 0.992)
Recombinant 0.464 (0.251 to 0.692) 0.918 (0.806 to 0.968)
For ACA there were insufficient data to analyse the effect of antigen used, so ACA is not in the table. 95 % CI = 95 % confidence interval. *Insufficient data to
analyse whole cell assays and purified antigen assays separately
Table 6 Year of publication
Year of publication Sensitivity (95 % CI) Specificity (95 % CI)
Erythema migrans <2000 0.631 (0.515 to 0.733) 0.897 (0.818 to 0.944)
2000 or later 0.853 (0.724 to 0.928) 0.929 (0.826 to 0.973)
Neuroborreliosis <2000 0.631 (0.515 to 0.733) 0.897 (0.818 to 0.944)
2000 or later 0.853 (0.724 to 0.928) 0.929 (0.826 to 0.973)
95 % CI = 95 % confidence interval
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our review, we found prevalences ranging from 1 to 79 %
for unspecified Lyme borreliosis and ranging from 12 to
62 % for neuroborreliosis. Appendix 3 shows some more of
these inferences, for different prevalence situations and dif-
ferent sensitivity and specificity of the tests.
Limitations of this review are the representativeness of
the results, the poor reporting of study characteristics
and the lack of a true gold standard. Most studies included
were case-control studies. These may be easier to perform
in a laboratory setting than cross-sectional designs, but
their results are less representative for clinical practice. Also
the immunoblot was not analysed in a way that is represen-
tative for practice: most immunoblots were analysed on the
same samples as the ELISAs, while in practice immunoblots
will only be used on ELISA-positive samples. EM patients
formed the second largest group of patients in our review.
The low sensitivity in this group of patients supports the
guidelines stating that serological testing in EM patients is
not recommended [86]. On the other hand, patients with
atypical manifestations were not included in the reviewed
studies, while this group of patients does form a diagnostic
problem [87, 88]. A more detailed analyses of the included
patients’ characteristics and test characteristics would have
been nice, but these characteristics were poorly reported.
This is also reflected in the Quality-assessment table, with
many ‘unclear’ scores, even for more recent studies.
Authors may not have been aware of existing reporting
guidelines and we therefore suggest that authors of future
studies use the STAndards for Reporting Diagnostic accur-
acy studies (STARD) to guide their manuscript [89].
There is no gold standard for Lyme borreliosis, so we
used the reference standard as presented by the authors
of the included studies. This may have added to the
amount of variation. Furthermore, many of the investi-
gated studies included the results from antibody testing
in their definition of Lyme borreliosis, which may have
overestimated sensitivity and specificity. However, this
was not proven in our heterogeneity analyses.
The performance of diagnostic tests very much depends
on the population in which the test is being used. Future
studies should therefore be prospective cross-sectional
studies including a consecutive sample of presenting pa-
tients, preferably stratified by the situation in which the
patient presents (e.g. a tertiary Lyme referral center versus
general practice). The lack of a gold standard may be
solved by using a reference standard with multiple levels
of certainty [90, 91]. Although this will diminish con-
trasts and will thus be more difficult to interpret, it
does reflect practice in a better way. Other solutions
may be more statistically derived approaches like latent
class analysis, use of expert-opinion and/or response to
treatment [92].
However, more and better designed diagnostic accur-
acy studies will not improve the accuracy of these tests
themselves. They will provide more valid estimates of
the tests’ accuracy, including predictive values, but the
actual added value of testing for Lyme disease requires
information about subsequent actions and consequences
of testing. If the final diagnosis or referral pattern is
solely based upon the clinical picture, then testing pa-
tients for Lyme may have no added value. In that case, a
perfect test may still be useless if it does not change clin-
ical management decisions [93]. On the other hand, im-
perfect laboratory tests may still be valuable for clinical
decision making if subsequent actions improve the pa-
tient’s outcomes. The challenge for clinicians is to deal
with the uncertainties of imperfect laboratory tests.
Conclusions
We found no evidence that ELISAs have a higher or lower
accuracy than immunoblots; neither did we find evidence
that two-tiered approaches have a better performance
than single tests. However, the data in this review do not
provide sufficient evidence to make inferences about the
value of the tests for clinical practice. Valid estimates of
sensitivity and specificity for the tests as used in practice
require well-designed cross-sectional studies, done in the
relevant clinical patient populations. Furthermore, infor-
mation is needed about the prevalence of Lyme borreliosis
among those tested for it and the clinical consequences of
a negative or positive test result. The latter depend on the
place of the test in the clinical pathway and the clinical
decisions that are driven by the test results or not. Future
research should primarily focus on more targeted clinical
validations of these tests and research into appropriate use
of these tests.
Availability of data and materials
The raw data (data-extraction results, reference lists,
statistical codes) will be provided upon request by ECDC
(info@ecdc.europa.eu).
Table 7 Early versus late Lyme borreliosis
Overall Early Lyme Late Lyme
Estimate (95 % CI) Estimate (95 % CI) Estimate (95 % CI)
Unspecified Lyme borreliosis Sensitivity 0.774 (0.468 to 0.930) 0.600 (0.323 to 0.826) 0.798 (0.554 to 0.926)
Specifcitiy 0.960 (0.852 to 0.990) 0.968 (0.904 to 0.990) 0.957 (0.875 to 0.986)
95 % CI = 95 % confidence interval
Leeflang et al. BMC Infectious Diseases  (2016) 16:140 Page 11 of 17
Appendix 1
Table 8 Search strategy
Search strategy in Ovidsp: database Embase 1980-present date search
January 10, 2013; for the update in February 2014 we used the same
strategy
Line# Term Results
1 exp serology/ 171111
2 serolog*.ti,ab,ot. 99141
3 antibod*.ti,ab,ot. 739175
4 exp antibody/ 745964
5 immunoglobin*.ti,ab,ot. 1034
6 IgG.ti,ab,ot. 119346
7 IgM.ti,ab,ot. 58826
8 exp enzyme linked immunosorbent assay/ 185612
9 ELISA.ti,ab,ot. 136569
10 exp immunoassay/ 343973
11 EIA.ti,ab,ot. 10028
12 immunosorbent.ti,ab,ot. 64523
13 immunofluorescent.ti,ab,ot. 16475
14 immunofluorescence.ti,ab,ot. 87513
15 immunoblot*.ti,ab,ot. 67674
16 “western blot”.ti,ab,ot. 98174
17 immunoassay.ti,ab,ot. 45568
18 exp lymphocyte transformation test/ 1200
19 “lymphocyte transformation test”.ti,ab,ot. 826
20 LTT.ti,ab,ot. 574
21 ((t-cell* or lymphocyte) adj15 (diagnostic or
diagnosis or diagnosing or screen* or test*)).mp.
41706
22 VIDAS.ti,ab,ot. 709
23 liason.ti,ab,ot. 104
24 Enzygnost.ti,ab,ot. 233
25 Serion.ti,ab,ot. 58
26 recomline.ti,ab,ot. 21
27 (virotech adj5 (europline or “line blot”)).ti,ab,ot. 1
28 euroimmunoblot.ti,ab,ot. 0
29 diacheck.ti,ab,ot. 2
30 euroimmun.ti,ab,ot. 191
31 Medac.ti,ab,ot. 136
32 mikrogen$.ti,ab,ot. 78
33 virotech.ti,ab,ot. 53
34 ELISPOT.ti,ab,ot. 5408
35 exp enzyme linked immunospot assay/ 4884
36 (c6 adj3 immunetics).ti,ab,ot. 5
37 or/1-36 1629954
38 lyme.ti,ab,ot. 10067
39 Lyme borreliosis/ 11571
Table 8 Search strategy (Continued)
40 tick borne disease/ 1803
41 exp tick bite/ 1956
42 (tick adj2 bite).ti,ab,ot. 1400
43 Neuroberreliosis.ti,ab,ot. 0
44 exp erythema chronicum migrans/ 1641
45 erythema migrans.ti,ab,ot. 1187
46 “erythema chronicum migrans”.ti,ab,ot. 433
47 exp Acrodermatitis chronica atrophicans/ 155
48 “Acrodermatitis chronica atrophicans”.ti,ab,ot. 426
49 meningoradiculitis.ti,ab,ot. 269
50 lyme.ti,ab,ot. 10067
51 Lyme borreliosis/ 11571
52 tick borne disease/ 1803
53 exp tick bite/ 1956
54 (tick adj2 bite).ti,ab,ot. 1400
55 Neuroborreliosis.ti,ab,ot. 1091
56 exp erythema chronicum migrans/ 1641
57 erythema migrans.ti,ab,ot. 1187
58 “erythema chronicum migrans”.ti,ab,ot. 433
59 exp Acrodermatitis chronica atrophicans/ 155
60 “Acrodermatitis chronica atrophicans”.ti,ab,ot. 426
61 meningoradiculitis.ti,ab,ot. 269
62 lyme.ti,ab,ot. 10067
63 Lyme borreliosis/ 11571
64 tick borne disease/ 1803
65 exp tick bite/ 1956
66 (tick adj2 bite).ti,ab,ot. 1400
67 exp erythema chronicum migrans/ 1641
68 erythema migrans.ti,ab,ot. 1187
69 “erythema chronicum migrans”.ti,ab,ot. 433
70 exp Acrodermatitis chronica atrophicans/ 155
71 “Acrodermatitis chronica atrophicans”.ti,ab,ot. 426
72 meningoradiculitis.ti,ab,ot. 269
73 Neuroborreliosis.ti,ab,ot. 1091
74 or/38-73 16588
75 exp Borrelia/ 10262
76 borrelia.ti,ab,ot. 8824
77 burgdorferi.ti,ab,ot. 7378
78 Borrelia infection/ 2668
79 or/75-78 12748
80 VLsE.ti,ab,ot. 142
81 OspC.ti,ab,ot. 446
82 or/80-81 551
83 74 or 79 20529
84 82 or 83 20551
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Appendix 2 Data quality
Patient selection
Risk of bias, signalling questions
– Was a case-control design avoided?
○ Case-control designs, especially if they include
healthy controls, possess ahigh risk of bias. Therefore,
all case-control studies are automatically judged to be
of high riskof bias in theoverall judgment.
– Was a consecutive or random sample of patients
enrolled?
– Did the study avoid inappropriate exclusions?
– Overall judgment:
○ Case-control studies always scored as high risk
of bias
○ Cross-sectional studies only low risk of bias if
other two signalling questions are scored as
‘yes’. If one of them is scored ‘no’, then high risk
of bias. Otherwise unclear.
Concerns regarding applicability
This is about the extent to which the patients (both
cases and controls) included in this study are representative
for the patients in which these serology tests will be used.
– Is there concern that the included patients do not
match the review question?
○ All case-control studies automatically high con-
cern. All cross-sectional studies automatically
low concern, except when no clear case-
definition has been used.
○ One study only included facial palsy patients→
high concern: applicable, but not representative
group
○ One study only included arthritic patients→ high
concern: applicable, but not representative group
Index test
Risk of bias, signalling questions
– Were the index test results interpreted without
knowledge of the results of the reference standard?
– If a threshold was used, was it pre-specified? By
selecting the cut-off value with the highest sensitivity
and/or specificity, researchers artificially optimize the
accuracy of their tests, which also may cause over-
estimation of sensitivity and specificity.
○ The first question is very poorly reported,
almost in all cases ‘unclear’.
○ The second question varies. Sometimes the
authors state that 95% value of the controls is
used as threshold, or that the mean of the
controls plus 2 or 3 SD is used as threshold.
Both variation have been scored as post-hoc.
– Overall judgment:
○ if the second question is scored as ‘yes’, then
automatically overall judgement also scored as
yes. This is because the first question will
usually be not reported or scored as ‘yes’.
○ If the latter is scored as unclear, then overall
also unclear; if latter is scored as no, then
overall high risk.
Concerns regarding applicability
This is about the extent to which the index test evalu-
ated is representative for the tests that will be used in
practice.
– Is there concern that the index test, its conduct or
interpretation differ from the review question?
○ All in-house tests automatically scored as high
concern
Risk of bias and concerns regarding applicability
should be scored for each test separately.
Reference Standard
Risk of bias, signalling questions
– Is the reference standard likely to correctly classify
the target condition?
○ Assumption: this will be likely in case-control
studies that used the ‘correct’ case-definitions
(e.g. Stanek [1], WHO)
○ For cross-sectional studies also likely for studies
that used the ‘correct’ case-definitions.
○ Studies using Western blot as reference
standard will be scored ‘no’ for this question.
– Were the reference standard results interpreted
without knowledge of the results of the index test?
○ Assumption: this will be likely in most case-
control studies, but only if serology was not
part of the case definition.
○ For the cross-sectional studies, this should be
explicitly stated.
– Overall judgement risk of bias:
Table 8 Search strategy (Continued)
85 37 and 84 7578
86 37 or 82 1630187
87 83 and 86 7789
88 85 or 87 7790
89 animal/not human/ 1348171
90 88 not 89 7369
91 review.pt. 1907269
92 90 not 91 6510
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○ case control studies with clear case-definitions
scored with low risk of bias;
○ case control studies with unclear/wrong case-
definitions score as unclear? Or high risk of bias?
○ Cross-sectional studies with a clear case-
definition and the second question scored as
‘yes’: low risk of bias.
○ Otherwise unclear, as latter question will be
very poorly reported?
Concerns regarding applicability
Is there concern that the target condition as defined by
the reference standard does not match the review
question?
– Western blot measures antibody response, while we
are interested in Lyme borreliosis, irrespective of
antibody status. So western blots are considered to
have high concerns regarding applicability.
– If serology included in case definition, then
incorporation bias and thus high risk of bias.
– If a case-control study used clear criteria and did
not include serology in these criteria, then Low
concern.
Risk of bias regarding flow and timing, signalling
questions
– Was there an appropriate interval between index
test(s) and reference standard?
○ We expected that in the cross-sectional designs
most tests would have been done around the
same moment as the final diagnosis was being
made. If we suspect the patient status may
have changed between the time of testing
and the moment of diagnosis, then we scored
this as ‘no’.
○ For case-control studies this was always scored
as ‘no’, as the determination of serology was
always done after the case-definitions were
defined, sometimes a long time after that was
done.
– Did patients receive the same reference standard?
○ Were scored as ‘no’ for all case-control studies,
as the controls were often from different settings,
different departments and had to fulfil different
criteria.
– Were all patients included in the analysis?
○ This was also scored ‘no’ for all case-control
studies.
– Overall judgment:
○ Case-control studies always scored high risk of
bias
○ For cross-sectional studies, we scored low risk of
bias if all three questions were scored ‘yes’ and
high risk of bias if at least one of them was
scored ‘no’. All other cases were scored ‘unclear’.
Appendix 3 Possible ranges in post-test
probability
The Tables A to D show the absolute numbers of true
positives, false positives, false negatives and true nega-
tives for a hypothetical cohort of 1000 patients.
These numbers should be taken with caution, as the
results were overall very heterogeneous. Furthermore, al-
though the prevalence does not influence estimates of
sensitivity and specificity extensively in our calculation,
this assumption requires further elaboration.
To take into account variation in results and uncer-
tainty, the calculations are made for different scenarios
and presented in Tables A to D.
Table A: varying sensitivities, at a fixed specificity of
95 % and a fixed prevalence of 10 %; Table B: varying
sensitivities, at a more realistic fixed specificity of 80 %
and a fixed prevalence of 10 %; Table C: varying specific-
ities, at a fixed sensitivity of 80 % and a fixed prevalence
of 10 %; Table D: sensitivity of 80 % and a specificity of
80 % and 95 %, at varying prevalence.
TABLE A: specificity=95 %,
prevalence=10 %
TABLE B: specificity=80 %,
prevalence=10 %
Sensitivity: TP FP FN TN Sensitivity: TP FP FN TN
0.90 90 45 10 855 0.90 90 180 10 720
0.85 85 45 15 855 0.85 85 180 15 720
0.80 80 45 20 855 0.80 80 180 20 720
0.75 75 45 25 855 0.75 75 180 25 720
0.70 70 45 30 855 0.70 70 180 30 720
0.60 60 45 40 855 0.60 60 180 40 720
0.50 50 45 50 855 0.50 50 180 50 720
TABLE C: sensitivity=80 %,
prevalence =10 %
TABLE D: sensitivity=80 %,
specificity=80 %/95 %
Specificity: TP FP FN TN Specificity: 0.95
0.99 80 9 20 891 Prevalence TP FP FN TN
0.95 80 45 20 855 0.05 40 48 10 903
0.90 80 90 20 810 0.10 80 45 20 855
0.85 80 135 20 765 0.20 160 40 40 760
0.80 80 180 20 720 Specificity: 0.80
0.75 80 225 20 675 Prevalence TP FP FN TN
0.70 80 270 20 630 0.05 40 190 10 760
0.65 80 315 20 585 0.10 80 180 20 720
0.60 80 360 20 540 0.20 160 160 40 640
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